Manuela Sum

Breisacher Str. 66
Freiburg, BW 79106, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Development of High-Affinity CHD1 Chromodomain Inhibitors.

Development of High-Affinity CHD1 Chromodomain Inhibitors.

Journal: Journal of medicinal chemistry

Published: May 05, 2026

Structure-Guided Design of a KMT9 Inhibitor Prodrug with Cellular Activity.

Structure-Guided Design of a KMT9 Inhibitor Prodrug with Cellular Activity.

Journal: Journal of medicinal chemistry

Published: June 17, 2025

Structure-Activity Studies of 1,2,4-Oxadiazoles for the Inhibition of the NAD+-Dependent Lysine Deacylase Sirtuin 2.

Structure-Activity Studies of 1,2,4-Oxadiazoles for the Inhibition of the NAD+-Dependent Lysine Deacylase Sirtuin 2.

Journal: Journal of medicinal chemistry

Published: June 07, 2024

Lysine Methyltransferase 9 (KMT9) Is an Actionable Target in Muscle-Invasive Bladder Cancer.

Lysine Methyltransferase 9 (KMT9) Is an Actionable Target in Muscle-Invasive Bladder Cancer.

Journal: Cancers

Published: February 13, 2024

Mitochondrial KMT9 methylates DLAT to control pyruvate dehydrogenase activity and prostate cancer growth.

Mitochondrial KMT9 methylates DLAT to control pyruvate dehydrogenase activity and prostate cancer growth.

Journal: Nature communications

Published: July 27, 2023

Structure-guided design of a selective inhibitor of the methyltransferase KMT9 with cellular activity.

Structure-guided design of a selective inhibitor of the methyltransferase KMT9 with cellular activity.

Journal: Nature communications

Published: July 03, 2023

Development of a NanoBRET assay to validate inhibitors of Sirt2-mediated lysine deacetylation and defatty-acylation that block prostate cancer cell migration.

Development of a NanoBRET assay to validate inhibitors of Sirt2-mediated lysine deacetylation and defatty-acylation that block prostate cancer cell migration.

Journal: RSC chemical biology

Published: December 16, 2021

KMT9 monomethylates histone H4 lysine 12 and controls proliferation of prostate cancer cells.

KMT9 monomethylates histone H4 lysine 12 and controls proliferation of prostate cancer cells.

Journal: Nature structural & molecular biology

Published: November 22, 2018

The histone code reader Spin1 controls skeletal muscle development.

The histone code reader Spin1 controls skeletal muscle development.

Journal: Cell death & disease

Published: May 04, 2017

Showing 1-9 of 9

Last Updated: 09/26/2026